Stem cell treatment via inhaler for lung fibrosis
Part of Lungs & breathing clinical trials.
This trial tests a new inhaled treatment made from placental stem cells to see if it's safe and helps slow scarring in the lungs (idiopathic pulmonary fibrosis). The treatment is breathed in through a nebulizer, similar to an asthma inhaler.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Confirmed diagnosis of idiopathic pulmonary fibrosis (lung scarring disease)
- Lung function in a specific range: forced vital capacity 50–80% of normal, and DLCO 30–80% of normal
- On a stable dose of lung-protecting medication (nintedanib, pirfenidone, or nerandomilast) for at least 8 weeks
- Able to walk more than 150 meters in 6 minutes without stopping
- Willing to use contraception for 12 months after treatment if you can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new stem cell therapy made from menstrual blood (SC01009) for people with IPF. It may help reduce lung scarring and improve breathing. Participants must already be on standard IPF treatment.
This trial tests a cell therapy called REGEND007 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the treatment can help improve walking distance or lung function.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This trial tests a new drug called HRS-9813 for people with pulmonary fibrosis (scarring in the lungs) that continues to worsen. It looks at whether the drug can slow down the disease compared to a placebo.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.